MSKCC relies on the counsel of outside advisors, represented by its Board of Scientific Consultants (BSC), the guidance of its Board of Overseers and Managers, as well as many internal planning processes to support the planning and evaluation of the research programs and core facilities at the Center. MSKCC has used the guidance it has received to develop and execute its initiatives for research and clinical expansion. During the past five years, the BSC has reviewed the research in many areas, including the Developmental and Stem Cell Biology Program, the Molecular Structure Program, the Prevention, Control and Population Research Program (now the Survivorship, Outcomes, and Risk Program), along with its efforts in Immigrant Health and Cancer Disparities, the Immunology and Transplantation Program, the Imaging and Radiation Sciences Program, the Cancer Biology and Experimental Pathology Program, Experimental Therapeutics, and disease-specific components of the Clinical Research Program. The BSC has also reviewed some of the newly recruited junior investigators and the training programs that bring outstanding students to train in MSKCC's laboratories. In addition to the BSC, the senior leaders receive strategic counsel from the MSKCC Board of Overseers and Managers to provide both community and financial stewardship as well as tactical advice on Center policies. A Task Force was also created to internally evaluate the Cores'infrastructure, and several improvements have been enacted. Through input from program members and the Associate Directors, further collaborative research centers that foster interactions between laboratory and clinical investigators have also been established. The recommendations made by the BSC and other planning groups have led to program reorganizations, new faculty recruitments, shared resource development, and facility expansions.
MSKCC's planning and evaluation processes provide external and internal counsel for its research programs. The expert advice that it receives guides the development of its strategic initiatives so that it can best meet the mission of an NCI-designated Comprehensive Cancer Center.
|Orlow, I; Satagopan, J M; Berwick, M et al. (2015) Genetic factors associated with naevus count and dermoscopic patterns: preliminary results from the Study of Nevi in Children (SONIC). Br J Dermatol 172:1081-9|
|Carey, Bryce W; Finley, Lydia W S; Cross, Justin R et al. (2015) Intracellular ?-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518:413-6|
|Mosher, C E; Given, B A; Ostroff, J S (2015) Barriers to mental health service use among distressed family caregivers of lung cancer patients. Eur J Cancer Care (Engl) 24:50-9|
|Navi, Babak B; Reiner, Anne S; Kamel, Hooman et al. (2015) Association between incident cancer and subsequent stroke. Ann Neurol 77:291-300|
|Xu, Zhe; Wu, Chaochao; Xie, Fang et al. (2015) Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. J Proteome Res 14:422-33|
|Xu, Hong; Cheng, Ming; Guo, Hongfen et al. (2015) Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res 3:266-77|
|Gondo, Tatsuo; Poon, Bing Ying; Matsumoto, Kazuhiro et al. (2015) Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer. BJU Int 115:81-6|
|Ripley, R Taylor; McMillan, Robert R; Sima, Camelia S et al. (2014) Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma. Ann Thorac Surg 98:968-74|
|Ye, Jiangbin; Fan, Jing; Venneti, Sriram et al. (2014) Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov 4:1406-17|
|Lu, Zhigang; Xu, Jin; Xu, Mingming et al. (2014) Morphine regulates expression of *-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the *-opioid receptor (OPRM1) gene via miR-103/miR-107. Mol Pharmacol 85:368-80|
Showing the most recent 10 out of 836 publications